Plaintiff May Amend False Advertising Claims Against Bayer



DOCUMENTS
  • Opinion


LOS ANGELES - A California appellate court has allowed a plaintiff to restate with particularity claims accusing Bayer Corp. of false and misleading advertising of its now-withdrawn cholesterol drug Baycol. In re Baycol Cases I and II, No. B204943 (Calif. App., 2nd Dist.).

On Oct. 20, the California Court of Appeal, Second District, ruled that the trial court should have granted Bayer's demurrer with leave to amend, thereby allowing the plaintiff to amend his claims to allege that the drug maker's unfair, unlawful and deceptive acts in marketing Baycol caused him to purchase the drug.

In September 2001, Douglas Shaw …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Video Game Addiction Product Liability Litigation

March 29, 2024

MORE DETAILS



HarrisMartin's Masters of Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS